| Beacon Counseling Services Pllc | |
|
4205 State St Ste 5 Bismarck ND 58503-0623 | |
| (701) 214-5530 | |
| (701) 712-5587 |
| Full Name | Beacon Counseling Services Pllc |
|---|---|
| Speciality | Counselor |
| Location | 4205 State St Ste 5, Bismarck, North Dakota |
| Authorized Official Name and Position | Lory Beth Hellman (MEMBER) |
| Authorized Official Contact | 7017125802 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Beacon Counseling Services Pllc 4205 State St Ste 5 Bismarck ND 58503-0623 Ph: (701) 214-5530 | Beacon Counseling Services Pllc 4205 State St Ste 5 Bismarck ND 58503-0623 Ph: (701) 214-5530 |
| NPI Number | 1073110383 |
|---|---|
| Provider Enumeration Date | 10/08/2020 |
| Last Update Date | 06/09/2023 |
| Certification Date | 06/09/2023 |
| Medicare PECOS PAC ID | 5597141044 |
|---|---|
| Medicare Enrollment ID | O20221212003174 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073110383 | NPI | - | NPPES |
| Provider Name | Laura M Gitter |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356406243 PECOS PAC ID: 0446535660 Enrollment ID: I20170329002849 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Heather Ibach |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1972829950 PECOS PAC ID: 3971915661 Enrollment ID: I20201222002453 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Lory Hellman |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1972772515 PECOS PAC ID: 8123404670 Enrollment ID: I20240213004344 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Jennifer L Gatzke |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1902228547 PECOS PAC ID: 2769868215 Enrollment ID: I20240223003347 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Rebecca Mcconnachie |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1275566143 PECOS PAC ID: 5496131948 Enrollment ID: I20240304001395 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Erin King |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1538644331 PECOS PAC ID: 0547606352 Enrollment ID: I20240314001655 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Bernadette Scott |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1912576836 PECOS PAC ID: 8527404342 Enrollment ID: I20240314001793 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
| Provider Name | Torina Mcconnachie |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1689211237 PECOS PAC ID: 9638531742 Enrollment ID: I20240314001911 |
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
News Archive
Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.
Medication to treat high blood pressure (BP) in older patients appears to be associated with an increased risk for serious injury from falling such as a hip fracture or head injury, especially in older patients who have been injured in previous falls.
› Verified 4 days ago
Missouri River Health Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 425 E Avenue C, Bismarck, ND 58501 Phone: 701-712-9962 | |
Telehealth Physician Network, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 S 2nd St Ste 155, Bismarck, ND 58504 Phone: 833-484-6359 | |
Whole Person Recovery Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1138 Summit Boulevard, Bismarck, ND 58504 Phone: 701-224-1261 | |
Therapeutic Trauma And Counseling Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 517 La Paz Ave, Bismarck, ND 58503 Phone: 701-595-2414 | |
Thrive Child & Family Therapy Center Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 E Main Ave Ste 102, Bismarck, ND 58501 Phone: 701-989-0210 | |
Adapt, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1720 Burnt Boat Drive, Suite 108, Bismarck, ND 58503 Phone: 701-255-3717 |